Fulgent Genetics
Mixed Month for Diagnostics Stocks as 360Dx Top 30 Ticks up 1 Percent in November
Out of the 30 companies tracked by 360Dx, 13 saw their share prices increase, while 17 saw their stock prices decline.
Fulgent Genetics Q3 Core Revenues Climb 9 Percent
The company's core revenues, excluding COVID-19-related testing and sequencing, also grew 9 percent year over year.
Fulgent Genetics Wins VA Testing Contract Worth up to $99M
The agreement provides for up to $99 million for tests performed over a five-year period, ensuring access among the VA population.
Fulgent Genetics' Q2 Revenues Rise 5 Percent
The firm reiterated its full-year 2024 guidance and also increased its EPS guide.
Fulgent Genetics Q4 Core Revenues Rise 21 Percent
Including COVID-related sales, full revenues for the quarter increased approximately 4 percent compared to Q4 2022.
Nov 3, 2023
Fulgent Genetics Core Revenues Rise 17 Percent
Aug 4, 2023
Fulgent Genetics Core Revenues Jump 48 Percent
Jun 1, 2023
360Dx Top 30 Drops 6 Percent in May
Sep 1, 2022
360Dx Top 30 Tumbles in August
Apr 21, 2022
Jan 4, 2022